Watson/Baxter Ferrlecit
Executive Summary
Baxter will contribute 80 sales reps to help detail Watson's anemia drug Ferrlecit under a co-promotion agreement-in-principle announced March 14. Baxter's force will double the size of the Ferrlecit sales team; Watson employs 75 Ferrlecit reps. The deal gives Baxter the opportunity to supplement its renal care business with traditional pharmaceuticals. FDA approved the injectable iron product in 1999. Sales were about $140 mil. in 2001...
You may also be interested in...
Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order
A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.